Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on the Safety and Efficacy of Human IPSC-Derived Cardiomyocytes in the Treatment of End-Stage Heart Failure

NCT06866600 is registered in ClinicalTrials.gov with HELP Therapeutics Co., Ltd. as lead sponsor.

NCT NCT06866600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06866600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on the Safety and Efficacy of Human IPSC-Derived Cardiomyocytes in the Treatment of End-Stage Heart Failure
Lead sponsor
HELP Therapeutics Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
March 31, 2025
Completion date
December 31, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, heart failure at nyha stage iii or iv